Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Top Page
Rapport Therapeutics, Inc.
(NASDAQ:RAPP)
Select Model
Select Model
Rating:57Neutral
Price Target:
$35.00
▲(4.51% Upside)
Action:ReiteratedDate:03/10/26
The score is primarily constrained by pre-revenue financials, widening losses, and material cash burn, despite a strong low-leverage balance sheet. Technicals are supportive with an uptrend and healthy momentum, and the recent FDA clearance to move RAP-219 into Phase 3 is a notable positive catalyst, while valuation remains challenging due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
High equity and minimal debt provide durable financial flexibility for multi-year R&D programs. This low leverage supports funding of clinical trials without near-term solvency pressure, enabling the company to prioritize development choices and absorb trial cost variability.
Negative Factors
Pre-revenue status & widening losses
Being pre-revenue with accelerating net losses means the business lacks operational cash inflows and depends entirely on financing or existing equity to fund operations. Persistent negative earnings extend time to profitability and increase dilution risk if external capital is required.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
High equity and minimal debt provide durable financial flexibility for multi-year R&D programs. This low leverage supports funding of clinical trials without near-term solvency pressure, enabling the company to prioritize development choices and absorb trial cost variability.
Read all positive factors
Rapport Therapeutics, Inc. (RAPP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)324.06K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS Growth-37.07%
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding47,792,942
10 Day Avg. Volume280,720
30 Day Avg. Volume324,064
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.48K
Enterprise Value/Ebitda-9.82
Forecast
1Y Price Target
$45.75Price Target Upside36.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.36
Revenue Forecast (FY)$11.11M
Rapport Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its l...
How the Company Makes Money
null...
Rapport Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.02M | -839.00K | -112.00K | -15.00K |
| EBITDA | -124.08M | -77.47M | -34.66M | -10.35M |
| Net Income | -111.48M | -78.31M | -34.79M | -10.65M |
Balance Sheet | ||||
| Total Assets | 512.43M | 314.93M | 155.42M | 31.60M |
| Cash, Cash Equivalents and Short-Term Investments | 490.54M | 305.28M | 147.48M | 31.16M |
| Total Debt | 11.48M | 1.48M | 2.15M | 10.44M |
| Total Liabilities | 27.78M | 9.51M | 181.06M | 12.10M |
| Stockholders Equity | 484.65M | 305.43M | -25.63M | 19.50M |
Cash Flow | ||||
| Free Cash Flow | -88.09M | -67.23M | -28.82M | -3.53M |
| Operating Cash Flow | -87.47M | -64.83M | -27.18M | -3.24M |
| Investing Cash Flow | -187.47M | -170.14M | -78.86M | -5.28M |
| Financing Cash Flow | 270.79M | 221.63M | 145.14M | 39.69M |
Rapport Therapeutics, Inc. Technical Analysis
Positive
33.49
Price Trends
28.68
Positive
28.47
Positive
24.20
Positive
Market Momentum
1.02
Negative
65.64
Neutral
85.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPP, the sentiment is Positive. The current price of 33.49 is above the 20-day moving average (MA) of 29.25, above the 50-day MA of 28.68, and above the 200-day MA of 24.20, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 65.64 is Neutral, neither overbought nor oversold. The STOCH value of 85.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAPP.
Rapport Therapeutics, Inc. Risk Analysis
Rapport Therapeutics, Inc. disclosed 87 risk factors in its most recent earnings report. Rapport Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapport Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.75B | 4.97 | 30.60% | ― | 9.76% | 88.06% | |
57 Neutral | $1.61B | -12.79 | -28.85% | ― | ― | -37.07% | |
56 Neutral | $2.57B | -8.42 | -24.22% | ― | ― | 3.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $296.30M | -5.61 | -37.47% | ― | ― | 70.19% |
* Healthcare Sector Average
RAPP
Rapport Therapeutics, Inc.
33.69
24.71
275.17%
INVA
Innoviva
23.62
6.30
36.37%
ELVN
Enliven Therapeutics
42.93
26.41
159.87%
LENZ
LENZ Therapeutics
9.45
-10.97
-53.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.